CorMedix Company Profile (NYSEMKT:CRMD)

About CorMedix (NYSEMKT:CRMD)

CorMedix logoCorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CRMD
  • CUSIP: N/A
  • Web:
  • Market Cap: $36.07 million
  • Outstanding Shares: 59,230,000
Average Prices:
  • 50 Day Moving Avg: $0.53
  • 200 Day Moving Avg: $0.55
  • 52 Week Range: $0.32 - $2.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.18
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $341,892.00
  • Price / Sales: 105.50
  • Book Value: $0.26 per share
  • Price / Book: 2.35
  • EBITDA: ($30,190,000.00)
  • Net Margins: -3,779.25%
  • Return on Equity: -156.33%
  • Return on Assets: -114.39%
  • Average Volume: 1.31 million shs.
  • Beta: 0.24
  • Short Ratio: 10.36

Frequently Asked Questions for CorMedix (NYSEMKT:CRMD)

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEMKT:CRMD) released its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.08. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $0.05 million. CorMedix had a negative return on equity of 156.33% and a negative net margin of 3,779.25%. View CorMedix's Earnings History.

When will CorMedix make its next earnings announcement?

CorMedix is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for CorMedix.

Where is CorMedix's stock going? Where will CorMedix's stock price be in 2017?

3 brokers have issued 12 month target prices for CorMedix's stock. Their forecasts range from $3.00 to $4.00. On average, they expect CorMedix's share price to reach $3.67 in the next year. View Analyst Ratings for CorMedix.

Who are some of CorMedix's key competitors?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:

  • Myron M. Kaplan, Chairman of the Board
  • Randy Milby, Chief Executive Officer, Director
  • Robert W. Cook, Chief Financial Officer
  • Antony E. Pfaffle M.D., Chief Scientific Officer, Director
  • Khoso Baluch, Director
  • Gary A. Gelbfish M.D., Director
  • Mehmood Khan M.D., Director
  • Janet M. Dillione, Independent Director
  • Matthew P. Duffy, Independent Director

How do I buy CorMedix stock?

Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CorMedix stock can currently be purchased for approximately $0.61.

MarketBeat Community Rating for CorMedix (NYSEMKT CRMD)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CorMedix (NYSEMKT:CRMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.67
Consensus Price Target History for CorMedix (NYSEMKT:CRMD)
Price Target History for CorMedix (NYSEMKT:CRMD)
Analysts' Ratings History for CorMedix (NYSEMKT:CRMD)
DateFirmActionRatingPrice TargetDetails
10/16/2017HC WainwrightSet Price TargetBuy$4.00View Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$5.00 -> $3.00View Rating Details
4/24/2017FBR & CoReiterated RatingBuyView Rating Details
11/16/2015Roth CapitalLower Price TargetNeutral$2.75 -> $2.50View Rating Details
(Data available from 10/22/2015 forward)


Earnings History for CorMedix (NYSEMKT:CRMD)
Earnings by Quarter for CorMedix (NYSEMKT:CRMD)
Earnings History by Quarter for CorMedix (NYSEMKT CRMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q3 2016($0.15)($0.23)$0.05 million$0.04 millionViewN/AView Earnings Details
8/5/2016Q216($0.11)($0.13)$119.97 million$16.51 millionViewN/AView Earnings Details
5/10/2016Q1($0.09)($0.12)$0.11 million$0.04 millionViewN/AView Earnings Details
11/12/2015Q3($0.13)($0.14)$0.12 million$0.04 millionViewListenView Earnings Details
8/6/2015Q2 2015($0.13)($0.13)$0.08 million$0.12 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.12)($0.09)$0.08 million$0.09 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)($0.09)$0.08 million$0.05 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)($0.26)$0.02 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CorMedix (NYSEMKT:CRMD)
Current Year EPS Consensus Estimate: $-0.530 EPS
Next Year EPS Consensus Estimate: $-0.280 EPS


Dividend History for CorMedix (NYSEMKT:CRMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CorMedix (NYSEMKT:CRMD)
Insider Trades by Quarter for CorMedix (NYSEMKT:CRMD)
Institutional Ownership by Quarter for CorMedix (NYSEMKT:CRMD)
Insider Trades by Quarter for CorMedix (NYSEMKT:CRMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/18/2017Khoso BaluchCEOBuy36,207$0.42$15,206.94View SEC Filing  
8/18/2017Mehmood KhanDirectorBuy400,000$0.39$156,000.00View SEC Filing  
8/17/2017Myron KaplanDirectorBuy80,000$0.40$32,000.00View SEC Filing  
8/14/2017Myron KaplanDirectorBuy50,000$0.35$17,500.00View SEC Filing  
5/30/2017Cora M TellezDirectorBuy7,550$0.42$3,171.00View SEC Filing  
5/17/2017Khoso BaluchCEOBuy75,000$0.48$36,000.00View SEC Filing  
5/16/2017Cora M TellezDirectorBuy50,000$0.48$24,000.00View SEC Filing  
5/15/2017Janet DillioneDirectorBuy21,231$0.48$10,190.88View SEC Filing  
5/15/2017Robert W CookCFOBuy50,000$0.50$25,000.00View SEC Filing  
5/1/2017Cora M TellezDirectorBuy4,800$0.66$3,168.00View SEC Filing  
3/30/2017Cora M TellezDirectorBuy1,950$1.66$3,237.00View SEC Filing  
2/28/2017Cora M TellezDirectorBuy1,540$2.10$3,234.00View SEC Filing  
2/7/2017Antony PfaffleInsiderSell10,000$2.00$20,000.00View SEC Filing  
1/30/2017Cora M TellezDirectorBuy1,780$1.79$3,186.20View SEC Filing  
12/30/2016Cora M TellezDirectorBuy1,990$1.58$3,144.20View SEC Filing  
12/9/2016Khoso BaluchCEOBuy10,000$1.77$17,700.00View SEC Filing  
11/30/2016Cora M TellezDirectorBuy1,800$1.80$3,240.00View SEC Filing  
10/31/2016Cora M TellezDirectorBuy1,475$2.15$3,171.25View SEC Filing  
10/21/2016Antony PfaffleInsiderSell20,000$2.23$44,600.00View SEC Filing  
9/22/2016Janet DillioneDirectorBuy15,000$2.66$39,900.00View SEC Filing  
8/25/2016Taunia MarkvickaDirectorBuy18,600$1.65$30,690.00View SEC Filing  
8/19/2016Cora M TellezDirectorBuy12,500$1.73$21,625.00View SEC Filing  
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.98View SEC Filing  
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.00View SEC Filing  
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.00View SEC Filing  
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.61View SEC Filing  
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.00View SEC Filing  
6/8/2016Janet DillioneDirectorBuy3,738$2.67$9,980.46View SEC Filing  
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.38View SEC Filing  
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00View SEC Filing  
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.00View SEC Filing  
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00View SEC Filing  
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.00View SEC Filing  
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.00View SEC Filing  
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CorMedix (NYSEMKT:CRMD)
Latest Headlines for CorMedix (NYSEMKT:CRMD)
Loading headlines, please wait.



CorMedix (CRMD) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.